Same target, different indications: ARP-1536

ARP-1536 is a humanized monoclonal antibody that targets the extracellular domain of VE-PTP. In preclinical models, ARP-1536 activated the Tie2 receptor in a dose-dependent manner with a pre-clinical efficacy profile similar to AKB-9778.

Based on the long half-life of monoclonal antibodies, ARP-1536 has the potential to be administered on a monthly to quarterly basis. We plan on developing ARP-1536 in combination with anti-VEGF therapy for the treatment of wet age-related macular degeneration and diabetic macular edema.

Click here to view publications on ARP-1536